Neurocrine Biosciences, Inc. (NBIX) Bundle
Ever wondered how a biopharmaceutical company navigates the complex world of neurological and endocrine-related disorders? Neurocrine Biosciences, Inc. (NBIX), with a market cap of over $13 Billion as of April 2024, stands as a key player, particularly noted for its focus on developing treatments for conditions with limited or inadequate therapeutic options. With a diverse portfolio and a commitment to innovation, how exactly does Neurocrine Biosciences operate and generate revenue in such a specialized field?
Neurocrine Biosciences, Inc. (NBIX) History
Neurocrine Biosciences, Inc. Founding Timeline
Year established
Neurocrine Biosciences was founded in 1992.
Original location
The company is headquartered in San Diego, California.
Founding team members
The founders of Neurocrine Biosciences include:
- Wylie Vale
- Jean Rivier
- Catherine Rivier
Initial capital/funding
Information regarding the initial capital and funding for Neurocrine Biosciences is not readily available in the provided search results.
Neurocrine Biosciences, Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 1996 | Initial Public Offering (IPO) | Neurocrine Biosciences became a publicly traded company, raising capital for further research and development. |
| 2010 | Phase III data of Varenicline for anxiety disorders | Demonstrated efficacy in treating anxiety disorders, although development was later discontinued. |
| 2015 | FDA approval of elagolix (ORILISSA) in collaboration with AbbVie | Approval of ORILISSA for the treatment of endometriosis-associated pain, marking a significant milestone and revenue stream. |
| 2017 | FDA approval of Ingrezza (valbenazine) | Approval of Ingrezza for the treatment of tardive dyskinesia, a major breakthrough and a primary revenue driver for the company. |
| 2020 | FDA approves Ingrezza for pediatric patients | Ingrezza was approved by the FDA for the treatment of pediatric patients, expanding its market reach. |
Neurocrine Biosciences, Inc. Transformative Moments
- Strategic Partnerships: Collaborations with companies like AbbVie significantly expanded the development and commercialization reach of Neurocrine's drugs, particularly with ORILISSA.
- Focus on Neurology and Endocrinology: The strategic decision to focus on neurological and endocrine disorders allowed Neurocrine to specialize and become a leader in these therapeutic areas.
- Successful Development and Approval of Ingrezza: The development and FDA approval of Ingrezza as the first drug for tardive dyskinesia marked a pivotal moment, establishing Neurocrine as a key player in the treatment of movement disorders.
For more insights into the company's investors, check out: Exploring Neurocrine Biosciences, Inc. (NBIX) Investor Profile: Who’s Buying and Why?
Neurocrine Biosciences, Inc. (NBIX) Ownership Structure
Neurocrine Biosciences, Inc. features a mixed ownership structure, encompassing institutional, retail, and insider stakeholders. The distribution of shares among these groups influences the company's governance and strategic direction.
Neurocrine Biosciences, Inc.'s Current Status
Neurocrine Biosciences, Inc. is a publicly traded company, meaning its shares are available for purchase on stock exchanges. This allows a wide range of investors to own a portion of the company.
Neurocrine Biosciences, Inc.'s Ownership Breakdown
Understanding the ownership breakdown of Neurocrine Biosciences provides insights into who has influence over the company's decisions. The following table summarizes the ownership percentages held by different types of shareholders:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutions | 93.74% | Institutional investors, such as mutual funds, pension funds, and hedge funds, hold a significant majority of Neurocrine Biosciences' shares. |
| Insiders | 0.64% | Insiders, including officers and directors of the company, own a small percentage of the shares. This indicates their direct financial stake in the company's performance. |
| Retail | 5.62% | Retail investors, or individual investors, hold the remaining percentage of shares. |
Neurocrine Biosciences, Inc.'s Leadership
The leadership team at Neurocrine Biosciences is responsible for the strategic direction and operational management of the company. Key members of the leadership team include:
- Kevin C. Gorman, Ph.D.: Chief Executive Officer
- Matt Abernethy: Chief Financial Officer
- Eiry W. Roberts, M.D.: Chief Medical Officer
These individuals, along with other members of the executive team, guide Neurocrine Biosciences in its mission to discover, develop, and commercialize innovative therapies for neurological and endocrine-related disorders.
For more insights into Neurocrine Biosciences' financial performance, explore: Breaking Down Neurocrine Biosciences, Inc. (NBIX) Financial Health: Key Insights for Investors
Neurocrine Biosciences, Inc. (NBIX) Mission and Values
Neurocrine Biosciences is dedicated to discovering and developing innovative therapies for neurological and endocrine-related disorders. The company places a high value on scientific rigor, patient needs, and ethical conduct.
Neurocrine Biosciences' Core Purpose
Official mission statement
Neurocrine Biosciences' mission statement is: 'To relieve suffering for people with great needs, but few options, by developing innovative therapies that target diseases with a high unmet need.'
Vision statement
Neurocrine Biosciences aims to be a leading neuroscience-focused biopharmaceutical company. Key aspects of their vision include:
- Developing and commercializing transformative therapies.
- Addressing significant unmet needs in neurological, endocrine, and psychiatric disorders.
- Improving the lives of patients and their families.
Company slogan/tagline
Neurocrine Biosciences does not have a single official slogan or tagline. However, their commitment to patients and innovation is reflected in their work. You might be interested in Exploring Neurocrine Biosciences, Inc. (NBIX) Investor Profile: Who’s Buying and Why?
Neurocrine Biosciences, Inc. (NBIX) How It Works
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. The company discovers and develops innovative therapies, often targeting under-addressed patient populations with unmet medical needs.
Neurocrine Biosciences, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| INGREZZA® (valbenazine) | Adults with tardive dyskinesia (TD) | Selective vesicular monoamine transport 2 (VMAT2) inhibitor; the first FDA-approved treatment for TD. In 2024, INGREZZA generated $1.6 billion in net product sales. |
| ONGENTYS® (opicapone) | Adults with Parkinson’s disease experiencing “off” episodes | A once-daily catechol-O-methyltransferase (COMT) inhibitor used as an add-on to levodopa/carbidopa. Neurocrine Biosciences collaborates with Mitsubishi Tanabe Pharma Corporation for its development and commercialization. |
| ORILISSA® (elagolix) | Women with moderate to severe endometriosis-associated pain | An oral gonadotropin-releasing hormone (GnRH) antagonist. Developed and commercialized in collaboration with AbbVie. In 2024, Neurocrine received $45 million in revenue from AbbVie related to ORILISSA. |
| পাবিনরিন (valbenazine) | Adults with chorea associated with Huntington’s disease | A selective vesicular monoamine transport 2 (VMAT2) inhibitor; the second FDA-approved treatment for chorea. |
Neurocrine Biosciences, Inc.'s Operational Framework
Neurocrine Biosciences operates through an integrated approach encompassing research and development, clinical trials, regulatory affairs, and commercialization. Key aspects of their operational framework include:
- Research and Development: Neurocrine focuses on identifying and developing novel drug candidates. This includes preclinical research, formulation development, and early-stage clinical trials.
- Clinical Trials: The company conducts Phase 1, 2, and 3 clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are crucial for obtaining regulatory approval.
- Regulatory Affairs: Neurocrine works closely with regulatory agencies like the FDA to ensure compliance and secure approval for its products. New Drug Applications (NDAs) are prepared and submitted for market authorization.
- Manufacturing and Supply Chain: While Neurocrine may outsource manufacturing, they maintain oversight of the production and supply chain to ensure product quality and availability.
- Commercialization: Upon approval, Neurocrine launches and markets its products through its sales force and marketing programs. This includes engaging with healthcare professionals and patient communities.
- Partnerships and Collaborations: Neurocrine often collaborates with other pharmaceutical companies to develop and commercialize products, sharing resources and expertise.
Neurocrine Biosciences, Inc.'s Strategic Advantages
Neurocrine Biosciences has several strategic advantages that contribute to its success in the biopharmaceutical industry:
- Specialized Focus: Neurocrine's focus on neurological, endocrine, and psychiatric disorders allows it to build deep expertise and a strong pipeline in these areas.
- Innovative Therapies: The company's ability to develop and bring to market first-in-class treatments, like INGREZZA for tardive dyskinesia, provides a significant competitive edge.
- Strong Intellectual Property: Patents and exclusivity periods for its products protect Neurocrine's market position and provide a period of market exclusivity.
- Strategic Collaborations: Partnerships with companies like AbbVie and Mitsubishi Tanabe Pharma enhance Neurocrine's capabilities and market reach.
- Established Commercial Infrastructure: A dedicated sales force and marketing team enable effective commercialization of approved products.
- Financial Performance: Strong revenue growth, driven primarily by INGREZZA, supports ongoing R&D efforts and business development activities. For example, in 2024, Neurocrine reported total revenues of $1.72 billion, with $1.6 billion coming from INGREZZA sales.
To gain more insights into the investors profile, you can check this link: Exploring Neurocrine Biosciences, Inc. (NBIX) Investor Profile: Who’s Buying and Why?
Neurocrine Biosciences, Inc. (NBIX) How It Makes Money
Neurocrine Biosciences primarily generates revenue through the development and commercialization of pharmaceutical products focused on neurological, endocrine, and psychiatric disorders.
Neurocrine Biosciences, Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| INGREZZA® (valbenazine) Sales | >95% | Increasing |
| Royalties and collaborations | <5% | Varies |
Neurocrine Biosciences, Inc.'s Business Economics
Neurocrine Biosciences, Inc.'s business economics are primarily driven by the sales of INGREZZA®, its leading product for the treatment of tardive dyskinesia. Key aspects of its business model include:
- Pricing Strategy: INGREZZA® commands a premium price reflecting its value as a novel treatment for a condition with limited therapeutic options.
- Market Exclusivity: Patents and regulatory exclusivities provide Neurocrine with a period of market protection, enhancing profitability.
- Research and Development: A significant portion of revenue is reinvested into R&D to expand the product pipeline and explore new indications for existing drugs.
- Collaborations: Strategic alliances with other pharmaceutical companies help to share development costs and broaden market reach.
Neurocrine Biosciences, Inc.'s Financial Performance
Neurocrine Biosciences, Inc.'s financial performance is characterized by strong revenue growth driven by INGREZZA®, but also significant R&D expenses. Key points include:
- Revenue Growth: Demonstrated by increasing sales of INGREZZA®, reflecting strong demand and market penetration. For example, in 2024, Neurocrine reported total revenues of $1.64 billion, an increase of 25% compared to 2023.
- Profitability: Achieving profitability depends on balancing revenue growth with operating expenses, particularly R&D investments.
- R&D Investment: Neurocrine continues to invest heavily in its pipeline. R&D expenses were $573.8 million in 2024.
- Cash Position: Maintaining a strong cash reserve is crucial for funding ongoing operations, R&D, and potential acquisitions. As of December 31, 2024, Neurocrine Biosciences had approximately $1.4 billion in cash, cash equivalents and marketable securities.
To gain more insights into Neurocrine Biosciences, Inc.'s financial health, explore: Breaking Down Neurocrine Biosciences, Inc. (NBIX) Financial Health: Key Insights for Investors
Neurocrine Biosciences, Inc. (NBIX) Market Position & Future Outlook
Neurocrine Biosciences is strategically positioned within the pharmaceutical industry, focusing on neurological, endocrine, and psychiatric disorders. With a robust portfolio and pipeline, the company is poised for continued growth, navigating both opportunities and challenges in a competitive market.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Neurocrine Biosciences | Approximately 3-5% (estimated) | Specialized focus on neurological and endocrine disorders; strong pipeline of innovative therapies. |
| Takeda Pharmaceutical | Approximately 8-10% (estimated) | Global presence; diverse portfolio including neurological drugs. |
| Teva Pharmaceutical Industries | Approximately 6-8% (estimated) | Extensive portfolio of generic and specialty medicines, including treatments for neurological conditions. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expansion of existing drug indications (e.g., Ingrezza) into new patient populations. | Clinical trial failures for pipeline products, impacting future revenue streams. |
| Strategic collaborations and acquisitions to broaden the product portfolio. | Regulatory hurdles and delays in drug approvals by the FDA. |
| Increasing awareness and diagnosis rates for tardive dyskinesia and other neurological disorders. | Competition from new market entrants and generic versions of existing drugs. |
Industry Position
Neurocrine Biosciences holds a significant position as a specialty pharmaceutical company focused on neurological and endocrine-related diseases. Key aspects of its industry standing include:
- Strong Focus on Innovation: Neurocrine is dedicated to developing innovative therapies, particularly in areas with unmet medical needs.
- Established Products: The company’s portfolio includes established products like Ingrezza, which contribute significantly to its revenue.
- Strategic Partnerships: Collaborations with other pharmaceutical companies enhance its research and development capabilities.
To gain more insight into the company's core values, explore: Mission Statement, Vision, & Core Values of Neurocrine Biosciences, Inc. (NBIX).
Neurocrine Biosciences, Inc. (NBIX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.